For women threatened with preterm labor, maintenance tocolysis with nifedipine is not associated with a significant reduction in adverse perinatal outcomes.
Pulmonary complications are under-recognized in systemic juvenile idiopathic arthritis (sJIA), and are often fatal.
Approaches for management of gout are presented in a two-part guideline.
Treatment with single-agent carfilzomib achieved durable responses in patients with relapsed/refractory multiple myeloma whose disease had relapsed after they received all available therapies (including bortezomib and immunomodulatory agents), suggesting that this agent has the potential to offer substantial clinical benefit. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.
Drugs in the Pipeline
Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company's LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.
The FDA has approved Promacta tablets (eltrombopag, from GlaxoSmithKline) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have been unresponsive to corticosteroids, immunoglobulins or splenectomy.
The FDA has approved Trivaris (triamcinolone acetonide injectable suspension, from Allergan), a synthetic glucocorticoid corticosteroid, for sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Baxter Healthcare has temporarily stopped manufacturing multi-dose vials of heparin sodium for injection due to reports of serious allergic reactions and hypotension in patients who receive high bolus doses of the drug.
The FDA has approved Triesence 40mg/mL (triamcinolone acetonide injectable suspension, from Alcon), a preservative-free synthetic corticosteroid for use in eye surgery and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.